ERBB2 and breast cancer: We explored cause-specific survival models with and without time invariant coefficients.<h4>Results</h4>Altogether 8.6% (2 542 patients) and 7.0% (3 125 patients) died from other causes and BC throughout the study period, respectively.Molecular subtype HR + /HER2-patients had similar BCSD and OCOD incidence rates.